Channel 1
Industry Satellite Symposia
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Medical need to improve on standard therapies for HR+/HER2- EBC (ID 334)
Lecture Time
19:00 - 19:05
Speakers
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Individualizing therapeutic decision-making for patients with HR+/HER2- EBC (ID 337)
Lecture Time
19:05 - 19:15
Speakers
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Adjuvant therapy for patients with HR+/HER2- EBC at high risk of recurrence (ID 338)
Lecture Time
19:15 - 19:30
Speakers
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Debating optimal neoadjuvant therapy (ID 336)
Lecture Time
19:30 - 19:40
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Future considerations on the horizon for HR+/HER2- EBC (ID 368)
Lecture Time
19:40 - 19:45
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00
CCO - CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer: Individualizing therapeutic decisions to improve patient outcomes
Industry Satellite Symposia
Summary, final thoughts and live Q&A (ID 339)
Lecture Time
19:45 - 19:55
Speakers
Room
Channel 1
Date
Wed, 05.05.2021
Time
19:00 - 20:00